Oruka Therapeutics (ORKA) Income towards Parent Company (2010 - 2024)

Oruka Therapeutics' Income towards Parent Company history runs 15 years deep, the most recent figure standing at -$18.1 million for Q2 2024.

• On a quarterly basis, Income towards Parent Company fell 1085.44% year-over-year to -$18.1 million in Q2 2024; TTM through Mar 2025 was -$18.1 million, a 58.4% decrease from a year earlier, with the FY2023 full-year figure at -$60.9 million, up 5.32% from the prior year.
• Income towards Parent Company declined to -$18.1 million in Q2 2024 per ORKA's latest filing, from -$7.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$1.1 million in Q4 2023 and bottomed at -$18.1 million in Q2 2024.
• The 5-year median for Income towards Parent Company is -$2.8 million (2022), against an average of -$3.9 million.
• Across the five-year window, Income towards Parent Company soared 79.32% in 2022 and plunged 1085.44% in 2024, its largest moves.
• Year by year, Income towards Parent Company stood at -$5.2 million in 2020, then decreased by 8.24% to -$5.7 million in 2021, then surged by 79.32% to -$1.2 million in 2022, then rose by 5.03% to -$1.1 million in 2023, then sank by 1521.35% to -$18.1 million in 2024.
• Per Business Quant, the three latest ORKA Income towards Parent Company figures stand at -$18.1 million (Q2 2024), -$7.0 million (Q1 2024), and -$1.1 million (Q4 2023).